---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-016069"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:45:25.453658+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix

## Summary
- CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).
- Planning Phase 1/2 clinical trial in Australia for diabetic foot ulcers in 2025, results expected Q3 2025.
- FDA IND clearance for CybroCell Phase 1/2 trial for degenerative disc disease, conditional on master cell bank.
- Expect to complete remaining CYWC628 pre-clinical studies (toxicity, dose titration) in Q3 2024.
- Manufacturing: planning CDMO transfer; master cell bank, working cell bank, and drug product by end of 2024.

## SEC filing metadata
- accession: 0001493152-24-016069
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224016069/0001493152-24-016069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224016069/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-016069
- JSON: https://secwatch.observer/filing/0001493152-24-016069.json
- Plain text: https://secwatch.observer/filing/0001493152-24-016069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.